代谢性危险因素与病毒性肝炎

摘要/Abstract

摘要： 代谢性危险因素包括中心性肥胖、肝脂肪变性、胰岛素抵抗、2型糖尿病和代谢综合征。慢性乙型肝炎和慢性丙型肝炎是两种常见的慢性肝病。近年来发现它们合并代谢综合征的病例越来越多。本文将对代谢性危险因素与病毒性肝炎的关系作一简要介绍。

关键词: 乙型肝炎, 丙型肝炎, 代谢性, 危险因素

段晓燕, 范建高. 代谢性危险因素与病毒性肝炎[J]. 实用肝脏病杂志, 2009, 12(6): 462-466.

[1] PISCHON T，BOEING H，HOFFMANN K，et al. General and abdominal adiposity and risk of death in Europe[J]. N Engl J Med，2008，359（20）：2105-2120.
[2] CHITTURI S，FARRELL GC. Fatty liver now，diabetes and heart attack later. The liver as a barometer of metabolic health[J]. J Gastroenterol Hepatol，2007，22（7）：967-969.
[3] FAN JG，Li F，CAI XB，et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol，2007，22（7）：1086-1091.
[4] TARGHER G，BERTOLINI L，PADOVANI R，et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease[J]. Diabetes Care，2006，29（6）：1325-1330. [5] HANLEY AJ，WILLIAMS K，FESTA A，et al. Elevations in markers of liver injury and risk of type 2 diabetes：the insulin resistance atherosclerosis study[J]. Diabetes，2004，53（10）：2623-2632.
[6] LUO B，WANG Y，WANG K. Association of metabolic syndrome and hepatitis B infection in a Chinese population[J].Clin Chim Acta，2007，380（1-2）：238-240.
[7] JAN CF，CHEN CJ，CHIU YH，et al. Apopulation-based study investigating the association between metabolic syndrome and hepatitis B/C infection（Keelung Community-based Integrated Screening study No.10）[J]. Int J Obes（Lond），2006，30：794-749.
[8] WONG GL，WONG VW，CHOI PC，et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J]. Gut，2009，58(1):111-117.
[9] CZAJA AJ，CARPENTER HA，SANTRACH PJ，et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C[J]. J Hepatol，1998，29（2）：198-206.
[10] ALTLPARMAK E，KOKLU S，YALINKILIC M，et al. Viral and host causes of fatty liver in chronic hepatitis B[J]. World J Gastroenterol，2005，11（20）：3056-3059.
[11] GORDON A，MCLEAN CA，PEDERSEN JS，et al. Hepatic steatosis in chronic hepatitis B and C: predictors，distribution and effect on fibrosis[J]. J Hepatol，2005，43（1）：38-44.
[12] THOMOPOULOS KC，ARVANITI V，TSAMANTAS AC，et al. Prevalence of liver steatosis in patients with chronic hepatitis B：a study of associated factors and of relationship with fibrosis[J]. Eur J Gastroenterol Hepatol，2006，18（3）：233-237.
[13] BONDINI S，KALLMAN J，WHEELER A，et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B[J]. Liver Int，2007，27（5）：607-611.
[14] CINDORUK M，KARAKAN T，UNAL S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection[J]. J Clin Gastroenterol，2007，41（5）：513-517.
[15] TSOCHATZIS E，PAPATHEODORIDIS GV，MANESIS EK，et al. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors：a comparative approach with genotype 1 chronic hepatitis C[J]. Dig Liver Dis，2007，39（10）：936-942.
[16] CHU CM，LIN DY，LIAW YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus（HBV）surface antigen in chronic HBV infection[J]. Int J Obes（Lond），2007，31（5）：871-875.
[17] WANG CC，HSU CS，LIU CJ，et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis[J]. J Gastroenterol Hepatol，2008，23（5）：779-782.[18] SHI JP，FAN JG，WU R，et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol，2008，23（9）：1419-1425.
[19] PENG D，HAN Y，DING H，et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J]. J Gastroenterol Hepatol，2008，23（7 Pt 1）：1082-1088.
[20] YUN JW，CHO YK，PARK JH，et al. Hepatic steatosis and fibrosis in young men with treatment-nave chronic hepatitis B[J]. Liver Int，2009，29（6）：878-883.
[21] MINAKARI M，MOLAEI M，SHALMANI HM，et al. Liver steatosis in patients with chronic hepatitis B infection：host and viral risk factors[J]. Eur J Gastroenterol Hepatol，2009，21（5）:512-516.
[22] PERSICO M，MASARONE M，LAMURA V，et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis：differences and similarities[J]. World J Gastroenterol，2009，15（4）：462-466
[23] ELLOUMI H，HEFAIEDH R，GARGOURI D，et al. Hepatic steatosis in chronic hepatitis B：contributing factors and effect on fibrosis[J]. Tunis Med，2008，86（11）:1000-1003.
[24] KUMAR M，CHAUHAN R， GUPTA N，et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients[J]. Gastroenterology，2009；136（4）：1272-1280.
[25] PARK SH，KIM DJ，LEE HY. Insulin resistance is not associated with histologic severity in nondiabetic，noncirrhotic patients with chronic hepatitis B virus infection[J]. Am J Gastroenterol，2009，104（5）：1135-1139.
[26] KIM KH，SHIN HJ，KIM K，et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology，2007，132（5）：1955-1967.
[27] NA TY，SHIN YK，ROH KJ，et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma[J]. Hepatology，2009，49（4）：1122-1131.[28] FARRELL GC，CHITTURI S，LAU GK，et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary[J]. J Gastroenterol Hepatol，2007，22（6）：775-777.
[29] SHIRATORI Y，YOSHIDA H，OMATA M. Management of hepatocellular carcinoma：advances in diagnosis，treatment and prevention[J]. Expert Rev Anticancer Ther，2001，1（2）：277-290.
[30] DORE GJ，FREEMAN AJ，LAW M，et al. Is severe liver disease a common outcome for people with chronic hepatitis C[J]. J Gastroenterol Hepatol，2002，17（4）：423-430. [31] MEHTA SH，BRANCATI FL，STRATHDEE SA，et al. Hepatitis C virus infection and incident type 2 diabetes[J].Hepatology，2003，38（1）：50-56.
[32] HUI JM，SUD A，FARRELL GC，et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected] [J]. Gastroenterology，2003，125（6）：1695-1704.
[33] TAMAKA N，NAGAYA T，KOMATSU M，et al. Insulin resistance and hepatitis C virus：a case-control study of non-obese，non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase[J]. Liver Int，2008，28（8）：1104-1111.
[34] DUSEJA A，DHIMAN RK，CHAWLA Y，et al. Insulin resistance is common in patients with redominantly genotype 3 chronic hepatitis C[J]. Dig Dis Sci，2009，54（8）：1778-1782.
[35] POUSTCHI H，NEGRO F，HUI J，et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3[J]. J Hepatol，2008，48（1）：28-34.
[36]CONJEEVARAM HS，KLEINER DE，EVERHART JE，et al. Race，insulin resistance and hepatic steatosis in chronic hepatitis C[J]. Hepatology，2007，45（1）：80-87.
[37] ZEIN NN，ETANERCEPT STUDY GROUP. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection：a phase 2 randomized， double-blind，placebo-controlled study[J]. J Hepatol，2005，42（3）:315-322.
[38] ROMERO-GóMEZ M，DEL MAR VILORIA M，ANDRADE RJ，et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients[J]. Gastroenterology，2005，128（3）:636-641.
[39]TSCCHATZIS EA，MANOLAKOPOULOS S，PAPATHEO-DORDIS GV，et al. Insulin resistance and metabolic syndrome in chronic liver diseases：old entities with new implications[J]. Scand J Gastroenterol， 2009，44（1）：6-14.
[40] LO IACONO O，VENEZIA G，PETTA S，et al. The impact of insulin resistance，serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C[J]. Aliment Pharmacol Ther，2007，25（10）:1181-1191.
[41] MANGIA A，MINERVA N，BACCA D，et al. Determinants of relapse after a short（12 weeks） course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection[J]. Hepatology，2009，49（2）：358-363.
[42] CHU CJ，LEE SD，HUNG TH，et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin[J]. Aliment Pharmacol Ther，2009，29（1）：46-54.
[43] DAI CY，HUANG JF，HSIEH MY，et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients[J]. J Hepatol，2009，50（4）：712-718.
[44] NASTA P，GATTI F，PUOTI M，et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a[J]. AIDS，2008，22（7）:857-861.
[45] ELGOUHARI HM， ZEIN CO，HANOUNEH I，et al. Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection[J]. Dig Dis Sci，2009.

代谢性危险因素与病毒性肝炎

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈帅, 杨长青. 门静脉血栓病因及危险因素研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 761-764.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[5]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	马丽英, 沈利娟. 妊娠后期应用替诺福韦治疗血清HBV高载量孕妇阻断HBV母婴传播的疗效及安全性分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 836-839.
[8]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[9]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[10]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[11]	杜科业, 杨东亮, 刘嘉. 慢性乙型肝炎与调节性T细胞研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 613-616.
[12]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[13]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[14]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[15]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.